SLC2A1 and paroxysmal dyskinesia: In previous studies, among patients with GLUT1-DS who were treated with the MAD, the frequency of seizures was reduced by 70-90, and >50% of patients exhibited an improvement in persistent motor disorder symptoms, such as paroxysmal dyskinesia or ataxia (41-43).